#	Pagina
attuale pagina	/open-h2020/projects/197029/index.html
-1	/open-h2020/projects/213206/deliverables.html
-2	/open-h2020/projects/213206/results.html
-3	/open-h2020/per-topic/protonation/list/index.html
-4	/open-h2020/projects/204919/results.html
-5	/open-h2020/per-topic/glcnac/list/index.html
-6	/open-h2020/per-topic/sendekia/list/index.html
-7	/open-h2020/per-topic/gh2ax/list/index.html
-8	/open-h2020/per-topic/hybead/list/index.html
-9	/open-h2020/projects/194914/results.html
-10	/open-h2020/per-topic/doxycycline/list/index.html

Opendata, web and dolomites

HTMD

Feasibility assessment of a cloud application platform for rational drug design using high throughput molecular dynamics

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

HTMD project word cloud

Explore the words cloud of the HTMD project. It provides you a very rough idea of what is the project "HTMD" about.

optimized global launch significantly throughput approved substantially subsequent larger viability computational rational accurate solution interactions identification interfaces drugs beginning environment simulation provides degree platform gain accuracy candidate htmd resource combines traction positioned progress inform market complexity cloud entry barrier translating reduce resolution invest trl limits dynamics productivity ready sme companies pace disruptive drug industry demonstration spending discovery leader silico virtualizing uniquely proposing pharmaceutical unnecessary simulations proprietary description preparations 1000m biological clinical expensive molecular competitiveness acellera speed interact workflows feasibility computationally prototyping md approximately pcr instrument looks proposes unprecedented

Project "HTMD" data sheet

The following table provides information about the project.

Coordinator	ACELLERA LABS SL Organization address address: C/ DELS PINZON 19 2-4 city: BARCELONA postcode: 8003 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2015-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ACELLERA LABS SL ACELLERA LABS SL Organization address address: C/ DELS PINZON 19 2-4 city: BARCELONA postcode: 8003 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	50˙000.00

Map

Project objective

The pharmaceutical industry’s increasing spending on R&D is not translating into new and better drugs at the pace required to maintain competitiveness. In-silico computational methods are beginning to gain traction in the progress towards more rational drug discovery workflows. Among the methods available, molecular dynamics (MD) provides the most accurate and useful description of molecular interactions, but the current state of the art has both a high degree of unnecessary technical complexity, and is computationally expensive. Together, these two factors have produced a high barrier to entry that substantially limits research productivity.Acellera looks to address these issues by proposing a cloud application platform for high-throughput MD (HTMD) simulations. This computational platform combines proprietary simulation technology - optimized for speed and simulation throughput – and user-friendly interfaces in a cloud environment to provide a novel resource for drug candidate identification. HTMD, which allows understanding with an unprecedented degree of resolution and accuracy how drugs interact with their biological targets, can significantly reduce the cost of pre-clinical research (PCR) by virtualizing key steps. It is currently estimated that pharmaceutical companies invest approximately 1000M Euro per approved drug. As a global leader in the development of technology for high-throughput molecular dynamics, Acellera is uniquely positioned to bring this disruptive computational technology to the market. The HTMD platform is ready for prototyping in an operational environment (TRL 6). Acellera proposes a Phase 1 SME Instrument to support the execution of a feasibility study into the market viability of the HTMD solution for pre-clinical research. Results of the study will be used to inform preparations for a larger-scale demonstration in Phase 2 and for the subsequent market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HTMD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HTMD" are provided by the European Opendata Portal: CORDIS opendata.